Based on observational data, a 2011 report highlighted an increased risk of pancreatitis and pancreatic cancer in patients using incretin therapy (Elashoff et al., 2011), prompting a warning from the Food and Drug Administration (FDA) regarding the pancreatic safety of GLP-1 RAs (Franks et al., 2012) further heightened concerns about the potential adverse effects of GLP-1RAs on the pancreas, resulting in elevated pancreatic enzymes and AP
Many patients mistakenly administered 5 to 20 times their intended dose, resulting in gastrointestinal issues, fainting, dehydration, pancreatitis, and gallstones leading to hospitalization
2026;DOI:10.1016/S0140-6736(26)00202-3
Can I receive IV therapy if I'm pregnant or breastfeeding
Continue to swirl until the powder has dissolved entirely
Product Quality Guarantee All peptides supplied by Battle Born Research undergo independent third-party HPLC verification confirming identity and purity